



Measuring the Quality of America's Health Care

September 28, 2005

Dear Colleague:

NCQA is pleased to provide you with the *HEDIS[®] 2006 Volume 2 Technical Update*. With this release, NCQA freezes the technical specifications for HEDIS 2006 Volume 2. The only measures not currently frozen are those that require the use of pharmacy data to identify denominator eligibility or numerator compliance. These measures will be final by November 1, 2005, when the NDC lists are posted.

This memo includes:

- Random Number (RAND) table for HEDIS 2006
- Corrections, policy changes and clarifications to *HEDIS 2006 Volume 2: Technical Specifications*.

Review these items and incorporate them into your implementation processes. HEDIS Compliance Auditors will consider these documents to be part of the specifications.

In addition to the changes, NCQA will not collect the Claims Timeliness measure for HEDIS 2006. This measure will be on hiatus and will undergo further analysis and refinement. The measure will not be included in the HEDIS 2006 data collection and reporting products (e.g., Data Submission Tool [DST], IDSS, *Quality Compass*). Refer to the Policy Update for further details on this decision and its impact on accreditation programs: [http://www.ncqa.org/Programs/Accreditation/MCO/claims timeliness policy update.pdf](http://www.ncqa.org/Programs/Accreditation/MCO/claims%20timeliness%20policy%20update.pdf)

Separate updates for HEDIS 2006 Volume 3 and Volume 5 will be released later this year. Specifications for these volumes will be frozen at that time.

If you have additional questions about information included in this Update or about other measure specifications, contact us through our Policy Clarification Support (PCS) system at www.ncqa.org/main/support.htm, or by phone (888-275-7585) or fax (202-955-3599).

We wish everyone a successful HEDIS data collection season!

Sincerely,

A handwritten signature in cursive script, appearing to read 'Cindy Ottone'.

Cindy Ottone, MHA
Director, Policy

Enclosure

Random Number (RAND) Table for Measures Using the Hybrid Method

Measure	RAND
Childhood Immunization Status	.21
Adolescent Immunization Status	.64
Colorectal Cancer Screening	.79
Cervical Cancer Screening	.11
Controlling High Blood Pressure	.05
Beta-Blocker Treatment After a Heart Attack	.63
Cholesterol Management for Patients With Cardiovascular Conditions	.51
Comprehensive Diabetes Care	.38
Prenatal and Postpartum Care*	.59
Frequency of Ongoing Prenatal Care*	.59
Well-Child Visits in the First 15 Months of Life	.83
Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life	.28
Adolescent Well-Care Visits	.24
Weeks of Pregnancy at Time of Enrollment in the MCO	.75

** Note: The Random Numbers for the Prenatal and Postpartum Care and Frequency of Ongoing Prenatal Care measures are the same. These measures are collected on the same denominator.*

Specification Updates

This document contains corrections, policy changes and clarifications to the *HEDIS 2006 Volume 2, Technical Specifications*. NCQA has identified the appropriate page number, measure or guideline and heading/subtitle for each item. NCQA’s operational definitions for corrections/policy changes and clarifications are as follows:

- **Correction/Policy Change:** A change made to an error in the 2006 specifications or notification of a revised requirement
- **Clarification:** Additional information that clarifies an existing 2006 measure or guideline.

Page	Measure/Guideline	Heading/Subtitle	Issue	Correction/Policy Change	Clarification
34	General Guidelines	General Guideline 37: Audit Designations	Immediately following Not Report, add the bulleted text: <ul style="list-style-type: none"> • The MCO did not produce an accurate survey sample frame for the survey measures. 		X
69	Childhood Immunization Status	Summary of Changes	Delete: Changed the timing requirements for IPV.		X
70	Childhood Immunization Status	DtaP/DT	Replace the first sentence with: An initial DtaP vaccination followed by at least three DtaP, DT or individual diphtheria and tetanus shots on or before the child’s second birthday.		X
73	Childhood Immunization Status	Table CIS-1/2	In the Hybrid cells, replace “Each of the 8 rates” with “Each of the 9 rates.”		X
77	Adolescent Immunization Status	Table AIS-1/2	In the Hybrid cells, replace “Each of the 5 rates” with “Each of the 4 rates.”		X
87	Inappropriate Antibiotic Treatment for Adults With Acute Bronchitis	Eligible Population: Allowable Gap	Replace the text with: No more than one gap of 45 days is permitted from 365 days prior to the Episode Date through 7 days after the Episode Date.		X
90	Inappropriate Antibiotic Treatment	Table AAB-F	Delete: Tobramycin, Trovafloxacin. Add: Ampicillin-sulbactam (Unasyn), Benzathine penicillin (Bicillin), Procaine penicillin (Wycillin) Corrected spelling for: Rifampin and Sulfadiazine.		X
93	Colorectal Cancer Screening	Table COL-A	Add ICD-9-CM code 45.43 to <i>Colonoscopy</i> .		X
93	Colorectal Cancer Screening	Hybrid Specification—Denominator	Replace the second sentence with: The MCO may reduce the sample size using the current year’s administrative rate or the prior year’s audited, product line-specific rate.		X

Page	Measure/Guideline	Heading/Subtitle	Issue	Correction/Policy Change	Clarification
94	Colorectal Cancer Screening	Note	Replace the third bullet with: <ul style="list-style-type: none"> There are two types of FOBT tests: guaiac (gFOBT) and immunochemical (iFOBT). Immunochemical FOBT tests may require fewer than three samples. Regardless of test type, for administrative data it is assumed that the required number of samples was returned; if the medical record data does not indicate how many samples were returned, it is assumed that the required number of samples was returned. If the medical record indicates that fewer than three samples were returned and does not indicate the type of test (guaiac or immunochemical), the member does not meet the screening criteria for inclusion in the numerator. However, if the medical record indicates that fewer than three samples were returned and an iFOBT was done, the member meets the screening criteria for inclusion in the numerator. 		X
96	Breast Cancer Screening	Table BCS-A	Add CPT code 76083.		X
106	Osteoporosis Management in Women Who Had a Fracture	Table OMW-A	Delete CPT codes 26600–26615, 28400–28485.		X
107	Osteoporosis Management in Women Who Had a Fracture	Table OMW-C	Add: Alendronate-cholecalciferol (Fosamax Plus D), ibandronate (Boniva), fluoride, vitamin D, calcium products, injectable estrogens		X
121	Cholesterol Management for Patients With Cardiovascular Conditions	Table CMC-A	Add: <ul style="list-style-type: none"> DRGs 555–558 to <i>PTCA</i> category. DRGs 547–550 to <i>CABG</i> category. Delete: <ul style="list-style-type: none"> CPT code 92998 from <i>PTCA</i> category. CPT codes 33542, 33545, 35500-35571 from <i>CABG</i> category. “-35671” (dash 35671); leave 35600 in the table in <i>CABG</i> category. 		X

Page	Measure/Guideline	Heading/Subtitle	Issue	Correction/Policy Change	Clarification
121	Cholesterol Management for Patients With Cardiovascular Conditions	Table CMC-B	<p>Add:</p> <ul style="list-style-type: none"> • DRG 140 to <i>Stable angina</i> category. • DRG 524 to <i>Ischemia</i> category. • DRG 559 to <i>Stroke</i> category. <p>Delete:</p> <ul style="list-style-type: none"> • DRG 015 from <i>Ischemia</i> category. <p>Replace ICD-9-CM range 438.0-438.42, 438.5, 435.6-438.9 with 438.</p>		X
122	Cholesterol Management for Patients With Cardiovascular Conditions	Hybrid Specification: LDL-C Level— <i>Medical record</i>	In the Friedewald equation, replace [lipoprotein] with [lipoprotein (a)].		X
123	Cholesterol Management for Patients With Cardiovascular Conditions	Table CMC-1/2/3	<p>Add a row and place a check mark in <i>Administrative data source</i> for Number of records excluded because of contraindications identified through administrative data.</p> <p>Add a row and place a check mark in <i>Hybrid data source</i> for Number of records excluded because of contraindications identified through medical record review.</p>		X
126	Comprehensive Diabetes Care	Administrative Specification: Numerators— <i>Poor HbA1c control</i>	<p>Replace the first paragraph with:</p> <p>Using automated laboratory data, identify the <i>most recent</i> HbA1c test during the measurement year. The member is numerator compliant if the most recent automated HbA1c level is >9.0% or is missing a result or if an HbA1c test was not done during the measurement year. The member is not numerator compliant if the automated result for the most recent HbA1c test during the measurement year is ≤9.0%.</p>		X
128	Comprehensive Diabetes Care	Table CDC-G	Add CPT code 36819 to the <i>Evidence of diagnosis of or treatment for nephropathy</i> category.		X
128	Comprehensive Diabetes Care	Hybrid Specification: Numerators— <i>Poor HbA1c control</i>	<p>Replace the first paragraph with:</p> <p>The <i>most recent</i> HbA1c level (performed during the measurement year) is >9.0% or is missing or was not done during the measurement year, as identified by automated laboratory data or medical record review. The member is not numerator compliant if the result for the most recent HbA1c test during the measurement year is ≤9.0%.</p>		X
130	Comprehensive Diabetes Care	Hybrid Specification: LDL-C Level— <i>Medical record</i>	In the Friedewald equation, replace [lipoprotein] with [lipoprotein (a)].		X

Page	Measure/Guideline	Heading/Subtitle	Issue	Correction/Policy Change	Clarification
136	Use of Appropriate Medications for People With Asthma	Note	Add a bullet: <ul style="list-style-type: none"> Plans should allocate the dispensing events to the appropriate year based on the date the prescription is filled. 		X
138	Use of Spirometry Testing in the Assessment and Diagnosis of COPD	Definitions: Negative Diagnosis History	Replace "720 days" with "730 days (2 years)." Add: For an Inpatient Index Episode, use the date of admission to determine the Negative Diagnosis History.		X
138	Use of Spirometry Testing in the Assessment and Diagnosis of COPD	Definitions: New Episode	Replace "720-day" with "730-day (2 year)."		X
138	Use of Spirometry Testing in the Assessment and Diagnosis of COPD	Eligible Population: Allowable gap	Replace the first sentence with: One gap is allowed in each of the 12 month periods prior to the IESD or in the 6-month period after the IESD, for a maximum of 2 gaps total.		X
139	Use of Spirometry Testing in the Assessment and Diagnosis of COPD	Step 3	Replace "720 days" with "730 days (2 years)." Add to Step 3: For an inpatient index episode, use the date of admission to determine the Negative Diagnosis History.		X
139	Use of Spirometry Testing in the Assessment and Diagnosis of COPD	Step 4	Replace "720 days" with "730 days (2 years)."		X
139	Use of Spirometry Testing in the Assessment and Diagnosis of COPD	Administrative Specification: <i>Numerator</i>	Replace "720 days" with "730 days (2 years)."		X
146	Antidepressant Medication Management	Administrative Specification	Add the following clarification to the second bullet: one telephone visit with a mental health or non-mental health practitioner.		X
154	Follow-Up Care for Children Prescribed ADHD Medication	Notes	Add a Notes section after the exclusions that includes: <ul style="list-style-type: none"> Members who switch product lines between the denominator 1 and denominator 2 continuous enrollment periods should only be included in denominator 1. Members who have multiple overlapping prescriptions should count the overlap days as once toward the days supplied. 		X
155	Glaucoma Screening in Older Adults	Table GSO-A	In the <i>General ophthalmologic services</i> category, replace CPT code 92005 with 92004. Add CPT code 92140 to the <i>Evaluation and management codes</i> category.		X

Page	Measure/Guideline	Heading/Subtitle	Issue	Correction/Policy Change	Clarification
160	Disease Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis	Table ART-A	Add CPT codes 99384, 99394 to the <i>Outpatient/non-acute inpatient services</i> category.		X
161	Disease Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis	Exclusions	Change the section head to: Exclusions (optional) .		X
165	Annual Monitoring for Patients on Persistent Medications	Table MPM-D	Add to Diuretics—Combination Products : <ul style="list-style-type: none"> • Eprosartan-hydrochlorothiazide (Teveten HCT). • Olmesartan-hydrochlorothiazide (Benicar HCT). • Enalaprilat (injectable). 		X
167	Annual Monitoring for Patients on Persistent Medications	Table MPM-G	Add to Statin combination products : Advicor		X
168	Annual Monitoring for Patients on Persistent Medications	Table MPM-I	Add DRGs 541-559.		X
169	Annual Monitoring for People on Persistent Medications	Table MPM-1/2/3	Replace “For each of the 5 rates and combined rate” with a check mark for Measurement year and Data collection methodology (administrative) elements.		X
171	Drugs to Be Avoided in the Elderly	Table DAE-A	Add to Antihistamines : Ephedrine, Hydroxyzine, Theophylline. Add to Amphetamines : Dexmethylphenidate. Add to Barbiturates : Amytal, Butalbital combinations. Add to Oral estrogen : estradiol (Estrace), ethinyl estradiol (Estinyl). Add to Others-Methyltestosterone : Nandrolone (Deca-Durabolin), oxandrolone (Oxandrin), stanozolol (Winstrol), testosterone (Andro, Testoderm, AndroGel, Striant), including injectables, oral, gel, films. The following injectables: Atropine, Premarin, Diazepam, Dicyclomine, Diphenhydramine, Dipyrindamole, Hydroxyzine, Ketorolac, Meperidine, Mesoridazine, Methocarbamol, Orphenadrine, Pentazocine, Pentobarbital, Phenobarbital, Promethazine, Scopolamine, Trimethobenzamide, Rectal Diastat, Pentobarbital, Promethazine, Scopolamine patches.		X
171	Drugs to Be Avoided in the Elderly	Note	Remove Note : <i>Plans have the option of reporting this measure based on therapeutic class...</i>		X
172	Drugs to Be Avoided in the Elderly	Table DAE-3	Remove data element: Numerator events by therapeutic class .		X

Page	Measure/Guideline	Heading/Subtitle	Issue	Correction/Policy Change	Clarification
191	Prenatal and Postpartum Care	Table PPC-B	Add ICD-9-CM code 674.51 to Step A.		X
192	Prenatal and Postpartum Care	Table PPC-C	Delete the double asterisks after CPT codes 59425 and 59426 and replace them with a single asterisk. Remove the double asterisk note from this page.		X
193	Prenatal and Postpartum Care	Table PPC-C	Add CPT codes 99241-99245, 99271-99275 to Part A of Decision Rule 2 .		X
193	Prenatal and Postpartum Care	Table PPC-C	Add the following LOINC codes to Decision Rule 2, Part C: TORCH—Cytomegalovirus: 5121-9, 5122-7, 5124-3, 5125-0, 5126-8, 5127-6, 7851-9, 7852-7, 7853-5, 9513-3, 13225-8, 13949-3, 15377-5, 16714-8, 16715-5, 16716-3, 22239-8, 22241-4, 22244-8, 22246-3, 22247-1, 22249-7, 24119-0, 30325-5, 32170-3, 32791-6, 32835-1, 34403-6.		X
193	Prenatal and Postpartum Care	Table PPC-C	Add CPT codes 86695, 86696 to Decision Rule 2, Part C: TORCH—Herpes simplex. Add the following LOINC codes to Decision Rule 2, Part C: TORCH – Herpes simplex: 5202-7, 5203-5, 5204-3, 5205-0, 5206-8, 5207-6, 5208-4, 5209-2, 5210-0, 7907-9, 7908-7, 7909-5, 7910-3, 7911-1, 7912-9, 7913-7, 9422-7, 10350-7, 13323-1, 13324-9, 13501-2, 13505-3, 14213-3, 16944-1, 16949-0, 16950-8, 16954-0, 16955-7, 16957-3, 16958-1, 17850-9, 17851-7, 19106-4, 21326-4, 21327-2, 22339-6, 22341-2, 22343-8, 24014-3, 25435-9, 25837-6, 25839-2, 26927-4, 27948-9, 30355-2, 31411-2, 32687-6, 32688-4, 32790-8, 32831-0, 32834-4, 32846-8, 33291-6, 34152-9, 34613-0, 36921-5, 40466-5, 40728-8, 40729-6, 41149-6, 41399-7.		X
193	Prenatal and Postpartum Care	Table PPC-C	Add the following LOINC codes to Decision Rule 2, Part C: TORCH—Toxoplasma: 5387-6, 5388-4, 5389-2, 5390-0, 5391-8, 8039-0, 8040-8, 11598-0, 12261-4, 12262-2, 13286-0, 15396-5, 17717-0, 21570-7, 22577-1, 22580-5, 22582-1, 22584-7, 23484-9, 23485-6, 23486-4, 23784-2, 24242-0, 24398-0, 24399-8, 25300-5, 25542-2, 33336-9, 33337-7, 34422-6, 35281-5, 35282-3, 40676-9, 40677-7, 40678-5, 40785-8, 40786-6.		X
193	Prenatal and Postpartum Care	Table PPC-C	Move the double asterisk note at the bottom of this page to the bottom of page 194.		X

Page	Measure/Guideline	Heading/Subtitle	Issue	Correction/Policy Change	Clarification
194	Prenatal and Postpartum Care	Table PPC-C	Add CPT codes 99241-99245, 99271-99275 to Part A of Decision Rule 3 .		X
194	Prenatal and Postpartum Care	Table PPC-C	Add the following LOINC codes to Decision Rule 3, Part C: TORCH—Cytomegalovirus: 5121-9, 5122-7, 5124-3, 5125-0, 5126-8, 5127-6, 7851-9, 7852-7, 7853-5, 9513-3, 13225-8, 13949-3, 15377-5, 16714-8, 16715-5, 16716-3, 22239-8, 22241-4, 22244-8, 22246-3, 22247-1, 22249-7, 24119-0, 30325-5, 32170-3, 32791-6, 32835-1, 34403-6.		X
194	Prenatal and Postpartum Care	Table PPC-C	Add CPT codes 86695, 86696 to Decision Rule 3, Part C: TORCH—Herpes simplex. Add the following LOINC codes to Decision Rule 3, Part C: TORCH—Herpes simplex: 5202-7, 5203-5, 5204-3, 5205-0, 5206-8, 5207-6, 5208-4, 5209-2, 5210-0, 7907-9, 7908-7, 7909-5, 7910-3, 7911-1, 7912-9, 7913-7, 9422-7, 10350-7, 13323-1, 13324-9, 13501-2, 13505-3, 14213-3, 16944-1, 16949-0, 16950-8, 16954-0, 16955-7, 16957-3, 16958-1, 17850-9, 17851-7, 19106-4, 21326-4, 21327-2, 22339-6, 22341-2, 22343-8, 24014-3, 25435-9, 25837-6, 25839-2, 26927-4, 27948-9, 30355-2, 31411-2, 32687-6, 32688-4, 32790-8, 32831-0, 32834-4, 32846-8, 33291-6, 34152-9, 34613-0, 36921-5, 40466-5, 40728-8, 40729-6, 41149-6, 41399-7.		X
194	Prenatal and Postpartum Care	Table PPC-C	Add the following LOINC codes to Decision Rule 3, Part C: TORCH—Toxoplasma: 5387-6, 5388-4, 5389-2, 5390-0, 5391-8, 8039-0, 8040-8, 11598-0, 12261-4, 12262-2, 13286-0, 15396-5, 17717-0, 21570-7, 22577-1, 22580-5, 22582-1, 22584-7, 23484-9, 23485-6, 23486-4, 23784-2, 24242-0, 24398-0, 24399-8, 25300-5, 25542-2, 33336-9, 33337-7, 34422-6, 35281-5, 35282-3, 40676-9, 40677-7, 40678-5, 40785-8, 40786-6.		X
195	Prenatal and Postpartum Care	Table PPC-C	Add CPT codes 99241-99245, 99271-99275 to Part A of Decision Rule 4 .		X

Page	Measure/Guideline	Heading/Subtitle	Issue	Correction/Policy Change	Clarification
195	Prenatal and Postpartum Care	Table PPC-D	<p>Replace the administrative instructions with: The member must meet criteria in Part A <i>or</i> (Part B <i>and</i> Part C).</p> <p>Delete from Part A:</p> <ul style="list-style-type: none"> • CPT codes 99201-99205, 99211-99215 • UB-92 Revenue code 514. <p>Add Part C: Part C: <i>Any one code.</i></p> <ul style="list-style-type: none"> • CPT code: 99201-99205, 99211-99215, 99241-99245, 99271-99275 • UB-92 Revenue code: 514. 		X
201	Annual Dental Visit	Table ADV-1	Replace "For each age stratification" with a check mark for Measurement year and Data collection methodology (administrative) elements.		X
204	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment	Table IET-A	Add CPT codes 99384, 99394.		X
204	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment	Table IET-A	Replace ICD-9-CM code range 303-304, 305.0, 305.2-305.9 with: 303.00-303.02, 303.90-303.92, 304.00-304.02, 304.10-304.12, 304.20-304.22, 304.30-304.32, 304.40-304.42, 304.50-304.52, 304.60-304.62, 304.70-304.72, 304.80-304.82, 304.90-304.92, 305.00-305.02, 305.20-305.22, 305.30-305.32, 305.40-305.42, 305.50-305.52, 305.60-305.62, 305.70-305.72, 305.80-305.82, 305.90-305.92.		X
206	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment	Table IET-1/2/3	Replace "For each age stratification" with a check mark for Measurement year and Data collection methodology (administrative) elements.		X
207-209	Claims Timeliness	Claims Timeliness	Remove Claims Timeliness from the HEDIS 2006 measurement set.	X	
212	Call Answer Timeliness	Table A7-1/2/3: Data Elements for Call Answer Timeliness	Replace Table A7-1/2/3 with Table CAT-1/2/3.		X
215	Call Abandonment	Table A8-1/2/3: Data Elements for Call Abandonment	Replace Table A8-1/2/3 with Table CAB-1/2/3.		X
241	Frequency of Ongoing Prenatal Care	Note	<p>Add a bullet:</p> <ul style="list-style-type: none"> • A prenatal visit on the date of delivery can count as a prenatal visit toward the Frequency of Ongoing Prenatal Care measure. 		X

Page	Measure/Guideline	Heading/Subtitle	Issue	Correction/Policy Change	Clarification
254	Frequency of Selected Procedures	Mastectomy	Add: Report bilateral mastectomy procedures as two procedures, even if performed on the same date.		X
254	Frequency of Selected Procedures	Lumpectomy	Add: Report multiple lumpectomies on the same date of service as one lumpectomy procedure per patient.		X
255	Frequency of Selected Procedures	Table FSP-A—Hysterectomy (abdominal)	Add CPT code 58956.		X
255	Frequency of Selected Procedures	Table FSP-A—Back surgery	Add: <ul style="list-style-type: none"> • CPT codes 22590, 22595-22614, 63045-63048, 63050, 63051 • ICD-9-CM codes 80.52, 84.6 • DRGs 496-498, 519, 520, 546. 		X
255	Frequency of Selected Procedures	Table FSP-A—Angioplasty (PTCA)	Add DRGs 555-558.		X
255	Frequency of Selected Procedures	Table FSP-A—Cardiac catheterization	Add DRGs 104, 535, 536.		X
255	Frequency of Selected Procedures	Table FSP-A—Coronary artery bypass graft (CABG)	Add DRGs 547-550.		X
255	Frequency of Selected Procedures	Table FSP-A—Mastectomy	Replace and categorize by the following: Bilateral: ICD-9 codes 85.42, 85.44, 85.46, 85.48; CPT codes 19180, 19182, 19200, 19220, 19240 with a modifier 50 code. Unilateral: ICD-9 codes 85.41, 85.43, 85.45, 85.47; CPT codes 19180, 19182, 19200, 19220, 19240 without a modifier 50 code; DRGs 257, 258. Delete CPT codes 19140, 19160, 19162.		X
255	Frequency of Selected Procedures	Table FSP-A—Lumpectomy	Add: <ul style="list-style-type: none"> • CPT codes 19160, 19162 • DRGs 259, 260, 262. 		X

Page	Measure/Guideline	Heading/Subtitle	Issue	Correction/Policy Change	Clarification
256-257	Frequency of Selected Procedures	Tables FSP-1, FSP-2—Member Months	Add to Member Months table: <ul style="list-style-type: none"> • <i>Commercial and Medicaid</i>: 20–44 for Male and Female. • <i>Medicaid</i>: 45–64 for Male. 		X
256-258	Frequency of Selected Procedures	Tables FSP-1, FSP 2—Back Surgery	Add to <i>Commercial and Medicaid</i> : <ul style="list-style-type: none"> • 20–44 (Male) and 20–44 (Female) • 45–64 (Male) and 45–64 (Female). Delete from <i>Commercial and Medicaid</i> : <ul style="list-style-type: none"> • 20–64 (Male and Female). 		X
263	Inpatient Utilization—General Hospital/Acute Care	Table IPU-A	Add DRGs 541–559.		X
264	Inpatient Utilization—General Hospital/Acute Care	Table IPU-B	Add DRGs 541–558 to <i>Surgery</i> category. Add DRG 559 to <i>Medicine</i> category.		X
266	Inpatient Utilization—General Hospital/Acute Care	Table IPU-1	Replace 65–75 age category with 65–74 for <i>Maternity</i> category.		X
284-285	Births and Average Length of Stay, Newborns	Table NEW-1 and NEW-2	Add asterisk under each table with the following note: “Other” includes female members ages 0–9 years, 50+ years and unknown age. Include all covered babies born to mothers who are not members of the MCO.		X
290	Mental Health Utilization—Percentage of Members Receiving Services	Table MPT-A	Add an asterisk to CPT codes 99217-99219.		X
291	Mental Health Utilization—Percentage of Members Receiving Services	Table MPT-B	Delete UB-92 Revenue codes 0905–0907 from the <i>Ambulatory UB-92 Revenue Codes</i> column. Add UB-92 Revenue codes 0905 and 0907 to the <i>Intermediate UB-92 Revenue Codes</i> column.		X
297	Identification of Alcohol and Other Drug Services	Table IAD-B	Add ICD-9-CM code 305.0.		X
298	Identification of Alcohol and Other Drug Services	Table IAD-C	Delete UB-92 Revenue codes 0905-0907 from the <i>Ambulatory UB-92 Revenue Codes</i> column. Add UB-92 Revenue codes 0905-0907 to the <i>Intermediate UB-92 Revenue Codes</i> column.		X

Page	Measure/Guideline	Heading/Subtitle	Issue	Correction/Policy Change	Clarification
299	Identification of Alcohol and Other Drug Services	Table IAD-1/2/3	Replace age range 34–64 with age range 35–64.		X
305	Antibiotic Utilization	Table ABX-A	Add: Cefadroxil hydrate. Delete: Tobramycin.		X
306	Antibiotic Utilization	Table ABX-C	Add to Cephalosporins : Cephradine (Velosef), Carbenicillin (Geopen), Piperacillin-tazobactam (Zosyn), Ticarcillin-clavulanate. Delete from Aminoglycosides : Tobramycin. Delete from Misc antibiotics : Fusidic acid.		X
307	Antibiotic Utilization	All other antibiotics	Replace end reference to Table ABX-4 with Table ABX-C.		X
308	Antibiotic Utilization	Tables ABX-1/2/3, ABX-1/2/3(a)	Add: Reporting Tables (see Attachment 1 below)		X
309-311	Antibiotic Utilization	Table ABX 1/2/3(a)-(c)	Add: <ul style="list-style-type: none"> • Male and Female to the “Unknown” indicator. • Total—Male, Total—Female, Total—Total to the “Total” indicator. 		X
339	Enrollment by State	Description	Replace “any time during the measurement year” with “as of December 31 of the measurement year.” Add: Anchor date—December 31 of the measurement year.		X
342	Race/Ethnicity Diversity of Membership	Table RDM-1/3	Add data field to table: Data Source . Data source values are: NR, CMS, MCO direct, Surname analysis/geo-coding, Multiple sources, Other.		X
343	Race/Ethnicity Diversity of Membership	Table RDM-1/3	Add Total—Male, Total—Female, Total—Total to the “Total” indicator.		X
345	Language Diversity of Membership	Table LDL-1/3	Add data field to table: Data Source . Data source values are: NR, CMS, MCO direct, Surname analysis/geo-coding, Multiple sources, Other.		X
345	Language Diversity of Membership	Table LDM-1/3	Replace the second sentence with: Each cell represents the proportion of members with identified demand for interpreter services and indicated spoken language of the total unduplicated count of members in the plan.		X

Page	Measure/Guideline	Heading/Subtitle	Issue	Correction/Policy Change	Clarification
346	Language Diversity of Membership	Table D6-B	Rename the table "Table LDM-1/3."		X
346	Language Diversity of Membership	Table D6-B	Add Total—Male, Total—Female, Total—Total to the "Total" indicator.		X
1-6	Appendix 1: Summary Table of Measures, Product Lines and Changes	Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication	Remove from the Medicare product line.		X
1-6	Appendix 1: Summary Table of Measures, Product Lines and Changes	Use of Imaging Studies for Low Back Pain	Remove from the Medicare product line.		X
1-7	Appendix 1: Summary Table of Measures, Product Lines and Changes	Annual Dental Visit	Remove from the commercial product line and add to the Medicaid product line.		X
2-3	Appendix 2: First-Year Measures	Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication	Remove from the Medicare product line and add to the commercial product line.		X
2-3	Appendix 2: First-Year Measures	Drugs to be Avoided in the Elderly	Remove from the commercial product line and add to the Medicare product line.		X
2-3	Appendix 2: First-Year Measures	Antibiotic Utilization	Add to the Medicare product line.		X

Attachment 1:

Table ABX-1/2/3: Plan Member Months

Member Months			
Age	Male	Female	Total
0-9	_____	_____	_____
10-17	_____	_____	_____
18-34	_____	_____	_____
35-49	_____	_____	_____
50-64	_____	_____	_____
65-74	_____	_____	_____
75-84	_____	_____	_____
85+	_____	_____	_____
Unknown	_____	_____	_____
Total:	_____	_____	_____

Reporting Table ABX 1/2/3(a): Antibiotic Utilization (Commercial, Medicaid, Medicare)

Age	Sex	Total Number of Antibiotic Scripts	Average Number of Antibiotic Scripts PMPY	Total Days Supplied for all Antibiotic Scripts	Average Days Supplied Per Antibiotic Scrip	Total Number of Scripts for Antibiotics of Concern	Average Number of Scripts PMPY for Antibiotics of Concern	Percentage of Antibiotics of Concern of all Antibiotic Scripts
0-9	Male	_____	_____	_____	_____	_____	_____	_____%
	Female	_____	_____	_____	_____	_____	_____	_____%
	Total:	_____	_____	_____	_____	_____	_____	_____%
10-17	Male	_____	_____	_____	_____	_____	_____	_____%
	Female	_____	_____	_____	_____	_____	_____	_____%
	Total:	_____	_____	_____	_____	_____	_____	_____%
18-34	Male	_____	_____	_____	_____	_____	_____	_____%
	Female	_____	_____	_____	_____	_____	_____	_____%
	Total:	_____	_____	_____	_____	_____	_____	_____%

Age	Sex	Total Number of Antibiotic Scrips	Average Number of Antibiotic Scrips PMPY	Total Days Supplied for all Antibiotic Scrips	Average Days Supplied Per Antibiotic Scrip	Total Number of Scrips for Antibiotics of Concern	Average Number of Scrips PMPY for Antibiotics of Concern	Percentage of Antibiotics of Concern of all Antibiotic Scrips
35-49	Male	_____	_____	_____	_____	_____	_____	_____%
	Female	_____	_____	_____	_____	_____	_____	_____%
	Total:	_____	_____	_____	_____	_____	_____	_____%
50-64	Male	_____	_____	_____	_____	_____	_____	_____%
	Female	_____	_____	_____	_____	_____	_____	_____%
	Total:	_____	_____	_____	_____	_____	_____	_____%
65-74	Male	_____	_____	_____	_____	_____	_____	_____%
	Female	_____	_____	_____	_____	_____	_____	_____%
	Total:	_____	_____	_____	_____	_____	_____	_____%